← Back
$LBRX All transactions

LB PHARMACEUTICALS INC

C

$ Value

Shares

411,681

Price

Filed

Sep 16

Insider

Name

Nussbaum Ran

Title

CIK

0001609805

Roles

Director

Transaction Details

Transaction Date

2025-09-12

Code

C

Table

Non-Derivative

Ownership

Indirect

Equity Swap

No

Shares After

411,681

Footnotes

Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering. | Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. | Consists of (i) 636,263 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 363,737 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. | Consists of (i) 6,362,625 shares of our redeemable convertible preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 3,637,375 shares of our redeemable convertible preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.

Filing Info

Accession No.

0001609805-25-000006

Form Type

4

Issuer CIK

0001691082

Nussbaum Ran's History

Date Ticker Type Value
2025-09-12 LBRX C
2025-09-12 LBRX $15.0M
2025-09-12 LBRX C
2025-09-10 LBRX A $0
2025-06-04 KROS A $0
2025-06-04 KROS A $0

Other Insiders at LBRX (90d)

Insider Bought Sold Last
Deep Track Biotechnology Master Fund, Ltd. $10.0M 2026-02-06
Lenz Robert A. 2026-03-06